{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 11,
  "pageCount": 53,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "appendix_disclosure",
  "function": "appendix",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "This appears to be a page from a legal or investigative report (likely a Congressional or regulatory report) rather than a standard consulting deck, but it is inventoried as requested.",
  "elementsJson": [
    "paragraph"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/11",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.11,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Former McKinsey Partner Sastry Chilukuri worked extensively for FDA and intermittently on Purdue matters. One McKinsey presentation to FDA in 2015 described him as a “[l]eader of McKinsey’s Healthcare Digital Practice” with “[d]eep FDA IT [information",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8019fe37-fec0-4eb4-96db-b8395eb6727b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Smith officially consulted on at least eight separate engagements for Purdue. A 2013 document, which McKinsey submitted to Purdue for use at an industry conference, stated that Mr. Smith possessed “extensive experience working with Purdue over the past 5 years on OxyContin related topics.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bbcc767-c3db-4107-af87-f21a00bf52fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Mr. Smith specifically dealt with Purdue’s efforts to obtain FDA approval of its opioid products, including projects on (1) securing regulatory approval at FDA of Purdue’s “BuTrans” opioid patch; (2) clinical studies to show the safety of pediatric OxyContin; and (3) preparing Purdue for an FDA Advisory Committee meeting on the safety of OXN Targiniq, another opioid product.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb371299-d83a-47dd-bf3d-98796fb72bd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.78,
        "x": 0.11,
        "y": 0.41
      },
      "kind": "paragraph",
      "text": "Even when not officially listed as consulting for projects at Purdue, internal McKinsey documents suggest Mr. Smith advised Purdue executives or discussed Purdue-related matters with other McKinsey colleagues consulting for the opioid manufacturer. For instance, although Mr. Smith did not appear to bill any hours to Purdue in 2016, documents obtained by the Committee show that he was invited to join at least 11 meetings or calls with or about Purdue that year.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4c2b256-33ae-4066-90b9-e8b7bb202d9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.78,
        "x": 0.11,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "By February 2014, Mr. Smith was participating in weekly conference calls with Purdue’s new CEO Mark Timney and a select group of McKinsey consultants. By late 2017, at the personal request of Purdue leadership, Mr. Smith was co-leading a project known as “Project Scottsdale” to transform Purdue’s entire business model. McKinsey held Mr. Smith out to the opioid manufacturer as the “Leader of McKinsey’s service to regulatory agencies globally.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e43bf096-ea31-4953-9ec7-a85dcfcce302",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.78,
        "x": 0.11,
        "y": 0.68
      },
      "kind": "source-note",
      "text": "24-30: Citations for the preceding text.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d076d7de-eae9-40e5-8e2d-f04439fdc045",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.18,
        "x": 0.17,
        "y": 0.51
      },
      "kind": "title",
      "text": "Sastry Chilukuri",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05985acd-4f0d-428e-a448-9f89007c7b41",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 6,
      "beatId": "ca9c3ab4-903c-4ff0-b53d-42335d2ce596",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents extensive evidence of McKinsey's conflicts of interest, including consultant overlaps and contract details.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}